59 results on '"Alcalay, Roy N."'
Search Results
2. Genetic Testing in Parkinson's Disease
3. Embracing Monogenic Parkinson's Disease: The MJFF Global Genetic PD Cohort
4. Patterns of TDP ‐43 Deposition in Brains withLRRK2 G2019SMutations
5. Defining the Riddle in Order to Solve It: There Is More Than One “Parkinson's Disease”
6. Differences in Sex‐Specific Frequency of Glucocerebrosidase Variant Carriers and Familial Parkinsonism
7. Polygenic Parkinson's Disease Genetic Risk Score as Risk Modifier of Parkinsonism in Gaucher Disease
8. Defining the Riddle in Order to Solve It: There Is More Than One “Parkinson's Disease”
9. Reply to: “Could Blood Hexosylsphingosine Be a Marker for Parkinson's Disease Linked withGBA1Mutations”?
10. Reply to: Cognitive Effects of Deep Brain Stimulation inGBA‐Related Parkinson's Disease
11. Attitudes Toward Telehealth Services Among People Living With Parkinson's Disease: A Survey Study
12. Impact of the <scp>COVID</scp> ‐19 Pandemic on Parkinson's Disease and Movement Disorders
13. Reply to: No Evidence that Glucosylsphingosine Is a Biomarker for Parkinson Disease
14. Parkinson Disease and Subthalamic Nucleus Deep Brain Stimulation: Cognitive Effects inGBAMutation Carriers
15. Plasma Glucosylsphingosine inGBA1Mutation Carriers with and without Parkinson's Disease
16. Neuropathological Findings in a Case of Parkinsonism and Developmental Delay Associated with a Monoallelic Variant in PLXNA1
17. Cytokines and Gaucher Biomarkers in Glucocerebrosidase Carriers with and Without Parkinson Disease
18. Reply to “ PPP2R5D Genetic Mutations and Early Onset Parkinsonism”
19. Analysis of Heterozygous PRKN Variants and Copy‐Number Variations in Parkinson's Disease
20. Early‐Onset Parkinsonism Is a Manifestation of thePPP2R5Dp. E200K Mutation
21. Elevated In Vitro Kinase Activity in Peripheral Blood Mononuclear Cells of Leucine‐Rich Repeat Kinase 2 G2019S Carriers: A Novel Enzyme‐Linked Immunosorbent Assay–Based Method
22. Precision Medicine for Parkinson's Disease: Ambroxol for Glucocerebrosidase‐Associated Parkinson's Disease, First Trial Completed
23. The Genetic Architecture of Parkinson Disease in Spain: Characterizing Population-Specific Risk, Differential Haplotype Structures, and Providing Etiologic Insight
24. Genetic, Structural, and Functional Evidence Link TMEM175 to Synucleinopathies
25. Knowledge and attitudes of Parkinson’s disease risk in the Gaucher population
26. Higher Urine bis(Monoacylglycerol)Phosphate Levels in LRRK2 G2019S Mutation Carriers: Implications for Therapeutic Development
27. Cancer outcomes among Parkinson's disease patients with leucine rich repeat kinase 2 mutations, idiopathic Parkinson's disease patients, and nonaffected controls
28. SMPD1 mutations, activity, and α‐synuclein accumulation in Parkinson's disease
29. Clinical and neuropathological features of progressive supranuclear palsy in Leucine rich repeat kinase ( LRRK2 ) G2019S mutation carriers
30. Neuropathology of genetic synucleinopathies with parkinsonism: Review of the literature
31. Patients’ Opinions on Genetic Counseling on the Increased Risk of Parkinson Disease among Gaucher Disease Carriers
32. Estimation of genetic risk function with covariates in the presence of missing genotypes
33. Frequency of GBA Variants in Autopsy-proven Multiple System Atrophy
34. Arm swing as a potential new prodromal marker of Parkinson's disease
35. The BioFIND study: Characteristics of a clinically typical Parkinson's disease biomarker cohort
36. Motor and Nonmotor Features of Carriers of the p.A53T Alpha‐Synuclein Mutation: A Longitudinal Study
37. Reply to letter: Plasma fasting cholesterol profiles and age at onset in Parkinson's disease
38. GBA mutations are associated with Rapid Eye Movement Sleep Behavior Disorder
39. Plasma apolipoprotein A1 associates with age at onset and motor severity in early Parkinson's disease patients
40. The relationship between obsessive-compulsive symptoms andPARKINgenotype: The CORE-PD study
41. Interest in Genetic Testing in Ashkenazi Jewish Parkinson’s Disease Patients and Their Unaffected Relatives
42. Parkinson's disease with Lewy bodies associated with a heterozygous PARKIN dosage mutation
43. Parkinson disease phenotype in Ashkenazi jews with and without LRRK2 G2019S mutations
44. Knowledge of and Interest in Genetic Results Among Parkinson Disease Patients and Caregivers
45. Somatic mitochondrial DNA mutations and parkinsonism
46. Lack of association between cancer history and PARKIN genotype: A family based study in PARKIN/Parkinson's Families
47. The neuropathology of genetic Parkinson's disease
48. The association between Mediterranean diet adherence and Parkinson's disease
49. Tremor severity and age: A cross-sectional, population-based study of 2,524 young and midlife normal adults
50. Transient exacerbation of ataxia with smoking: A prevalence survey
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.